Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial
Gaul C, Diener HC
Published in Journal of Headache and Pain
Methodology
Randomized placebo-controlled multicenter trial of a riboflavin, magnesium and coenzyme Q10 combination in migraine patients.
Key Findings
Migraine days and symptom burden decreased more with the mitochondrial cofactor combination than placebo, though the primary endpoint of migraine pain intensity was not met.
Conclusions
Mitochondrial cofactor support offers modest migraine benefit; the primary endpoint was null.
Limitations
Combination product prevents attribution to a single cofactor; primary endpoint not significant.
Supplements Studied
Migraine days decreased with a riboflavin, magnesium and coenzyme Q10 combination, though the primary endpoint was not met
Migraine days decreased more with the riboflavin, magnesium and coenzyme Q10 combination than placebo, though the primary endpoint was not met
Outcomes Measured
Migraine days decreased more with the riboflavin, magnesium and coenzyme Q10 combination than placebo, though the primary endpoint was not met
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.